Symbiotec Pharmalab IPO

Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients, nutritional ingredients, and specialty products. The company caters to domestic and international markets across regulated and emerging regions. It emphasizes research-driven manufacturing, quality compliance, and sustainable processes. Symbiotec Pharmalab Ltd. supports pharmaceutical, nutraceutical, and wellness industries by delivering high-quality, innovative ingredients aligned with global standards. With over 30 years of industry experience, they have evolved from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from the United States Food and Drug Administration (“US FDA”), European Union Good Manufacturing Practices (“EU-GMP”), Ministry of Food and Drug Safety, Korea and other global organisations. As of June 30, 2025, they had two operational industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (“MT”) and fermentation capacity of 300 kilolitres. Competitive Strengths: Global leadership in corticosteroid and steroidal-hormone APIs Long-standing relationships with domestic and global customer base Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record. Continuous investment in R&D, with leading technological capabilities among Indian peers. Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings

Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company General corporate purposes